馃 The 5 ALS Clinical Trials Everyone鈥檚 Watching in 2025
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig鈥檚 disease, continues to challenge the medical world鈥攂ut 2025 might just be a turning point. With a surge of promising therapies in the pipeline, researchers, patients, and caregivers alike are keeping their eyes locked on a handful of clinical trials that could change everything.
Here are the five ALS clinical trials generating the most buzz this year鈥攁nd why they matter.
1. Biogen鈥檚 Tofersen Expansion Trial
Tofersen, an antisense oligonucleotide therapy targeting the SOD1 gene mutation, has shown signs of slowing ALS progression in early studies. In 2025, Biogen is expanding this trial to test its efficacy in pre-symptomatic carriers. This could be monumental鈥攊t鈥檚 the first step toward preventative treatment for genetic ALS.
2. Amylyx鈥檚 AMX0035 Long-Term Efficacy Study
After receiving FDA approval in 2022, AMX0035 entered a long-term follow-up phase to assess how well the drug performs over time. 2025鈥檚 data will help determine if the benefits seen in initial trials truly hold up. For patients and physicians, this is a pivotal moment in deciding whether the drug should become a foundational therapy.
3. Clene Nanomedicine鈥檚 CNM-Au8 Regenerative Therapy Trial
This unique therapy uses gold nanocrystals to enhance brain energy metabolism. CNM-Au8 has already shown potential to improve neuron resilience and function. The 2025 trial is testing a higher dose over a longer duration. If it hits the mark, this could be the first regenerative-focused ALS therapy that works at the cellular level.
4. Calico & AbbVie鈥檚 Anti-Aging Angle
In a bold approach, Calico (Google鈥檚 longevity startup) and AbbVie are collaborating on a compound that targets aging pathways suspected to influence ALS progression. 2025 marks the first human trial phase. The industry is watching closely鈥攊f successful, this trial could open the door to a new class of ALS treatments that focus on slowing biological aging itself.
5. QurAlis鈥檚 Precision Neuro Therapy
This biotech firm is trialing a personalized neuroprotection therapy based on patient-specific biomarkers. QurAlis is betting big on tailoring treatment to the individual rather than a one-size-fits-all drug. With early preclinical success, its 2025 Phase 2 trial will test whether personalized ALS therapy could finally become reality.
